Primary cutaneous CD4‐positive small/medium‐sized pleomorphic T‐cell lymphoproliferative disorder: Report of a case and review of the literature

Primary cutaneous small/medium‐sized T‐cell lymphoma (PCSM‐TCL), which was included in the World Health Organization ‐ European Organization for Research and Treatment of Cancer (WHO‐EORTC) classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as prim...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cutaneous pathology 2017-11, Vol.44 (11), p.944-947
Main Authors: Keeling, Brett H., Gavino, Alde Carlo P., Admirand, Joan, Soldano, Anthony C.
Format: Article
Language:English
Subjects:
Cancer
Case reports
CD4 antigen
CD4-Positive T-Lymphocytes - pathology
dermatology
Humans
Literature reviews
Lymphocytes
Lymphocytes T
lymphoid neoplasms
lymphoma
lymphoproliferative disorder
Lymphoproliferative Disorders - pathology
Male
Middle Aged
Skin Diseases - pathology
T-cell lymphoma
Therapeutic applications
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary cutaneous small/medium‐sized T‐cell lymphoma (PCSM‐TCL), which was included in the World Health Organization ‐ European Organization for Research and Treatment of Cancer (WHO‐EORTC) classification for cutaneous lymphomas as a provisional entity in 2008, has recently been reclassified as primary cutaneous small/medium‐sized T‐cell lymphoproliferative disorder (PCSM‐TCLPD) because of its indolent behavior and uncertain malignant potential. Treatment with local therapies is usually curative, although there have been reports of aggressive, systemic disease. This spectrum of disease behavior evokes the consideration that this entity may actually be multiple diseases with a shared clinicopathologic features rather than a singular disease process with a variety of behaviors. PCSM‐TCLPD retained its designation as a provisional entity under the updated WHO‐EORTC guidelines; however, additional cases of PCSM‐TCLPD are needed to shed more light on this rare disorder.
ISSN:0303-6987
1600-0560
DOI:10.1111/cup.13011